Froget Séverine, Barthelemy Emmanuelle, Guillot François, Soler Christophe, Coudert Marie-Claude, Benbunan Marc, Dosquet Christine
Unité de Thérapie Cellulaire, Hôpital Saint-Louis AP-HP, 1, Avenue Claude Vellefaux 75475 Paris cedex 10, France.
Eur Cytokine Netw. 2003 Jan-Mar;14(1):60-4.
Cell and tissue therapy applications in humans are being used increasingly, particularly for tissue repair. Several reconstructed skin models have been proposed. Wound healing involves overlapping steps of inflammation, cell migration and proliferation, neovascularisation, extracellular matrix production and remodelling. This is regulated by numerous cytokines and other soluble mediators. We have prepared dermal substitutes (DS) consisting of a collagen-GAG, three-dimensional matrix colonized by human dermal fibroblasts (HDF), isolated by skin explant or enzymatic digestion of the skin for potential therapeutic use in humans. To test the functionality of these DS, we measured (ELISA) the stimulatory effect on HDF in the matrix, of serial dilutions of human serum (HS) on the production of wound healing mediators: interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF) and tissue inhibitor of metalloproteinase-1 (TIMP-1). We observed: 1). a stimulatory effect of HS on HDF production of the different mediators tested, with a dose-dependent effect in the case of IL-8 and VEGF. 2). A matrix-potentiating effect on the production of the different mediators by HDF. 3). A decrease in the production of IL-8 and VEGF when HDF isolated by enzymatic digestion was used to colonize the matrix as compared with HDF isolated by skin explant. We conclude: 1). that the production by HDF, in a collagen-GAG matrix, of mediators involved in cutaneous wound healing is decreased when HDF are isolated by enzymatic skin digestion rather than by skin explant. 2). That measurement of the production of cytokines or other mediators could be a useful quality control to test the functionality of tissue-engineered DS for tissue repair therapy in humans and more generally of cells prepared for cell therapy.
细胞和组织疗法在人类中的应用越来越广泛,尤其是用于组织修复。已经提出了几种重建皮肤模型。伤口愈合涉及炎症、细胞迁移和增殖、新血管形成、细胞外基质产生和重塑等多个重叠步骤。这是由多种细胞因子和其他可溶性介质调节的。我们制备了由胶原蛋白-糖胺聚糖组成的真皮替代物(DS),这是一种由人真皮成纤维细胞(HDF)定植的三维基质,通过皮肤外植体或皮肤酶消化分离得到,用于人类潜在的治疗用途。为了测试这些DS的功能,我们通过酶联免疫吸附测定法(ELISA)测量了人血清(HS)系列稀释液对基质中HDF产生伤口愈合介质的刺激作用:白细胞介素-8(IL-8)、血管内皮生长因子(VEGF)、角质形成细胞生长因子(KGF)和金属蛋白酶组织抑制剂-1(TIMP-1)。我们观察到:1). HS对所测试的不同介质的HDF产生有刺激作用,对于IL-8和VEGF呈剂量依赖性效应。2). 对HDF产生不同介质有基质增强作用。3).与通过皮肤外植体分离的HDF相比,当使用通过酶消化分离的HDF来定植基质时,IL-8和VEGF的产生减少。我们得出结论:1). 当通过皮肤酶消化而非皮肤外植体分离HDF时,在胶原蛋白-糖胺聚糖基质中,HDF产生的参与皮肤伤口愈合的介质会减少。2). 细胞因子或其他介质产生的测量可能是一种有用的质量控制方法,用于测试组织工程DS在人类组织修复治疗中的功能,更广泛地说,用于测试为细胞治疗制备的细胞的功能。